Cargando…
Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study
Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD a...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355423/ https://www.ncbi.nlm.nih.gov/pubmed/32485853 http://dx.doi.org/10.3390/jcm9061640 |
_version_ | 1783558271848677376 |
---|---|
author | Święcki, Przemysław Sawicki, Robert Knapp, Małgorzata Kamiński, Karol Adam Ptaszyńska-Kopczyńska, Katarzyna Sobkowicz, Bożena Lisowska, Anna |
author_facet | Święcki, Przemysław Sawicki, Robert Knapp, Małgorzata Kamiński, Karol Adam Ptaszyńska-Kopczyńska, Katarzyna Sobkowicz, Bożena Lisowska, Anna |
author_sort | Święcki, Przemysław |
collection | PubMed |
description | Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD after acute myocardial infarction (AMI). The analysis included 110 patients who were hospitalized due to AMI, treated with primary coronary intervention (PCI) and further attended a follow-up visit, and 100 healthy volunteers. The Gal-3 concentration and carotid ultrasound were evaluated at baseline and on a follow-up visit. We found that the Gal-3 concentration in the group with hyperlipidemia decreased during the observation (10.7 vs. 7.9 ng/mL, p = 0.00003). Patients rehospitalized during follow up had higher concentration of Gal-3 in the acute phase of myocardial infarction (MI) (10.7 vs. 7.2 ng/mL, p = 0.02; 10.1 vs. 8.0 ng/mL, p = 0.002, respectively). In the group of patients who had none of the following endpoints: subsequent MI, PCI, coronary artery bypass grafting (CABG) or stroke, there was a decrease in Gal-3 concentration at the follow-up visit. Parameters affecting the frequency of a composite endpoint occurrence are: the presence of atheromatous plaque in the carotid artery (p = 0.017), Gal-3 (p = 0.004) and haemoglobin (p = 0.03) concentration. In multivariate analysis, only Gal-3 concentration higher than 9.2 ng/mL at discharge was associated with a nine-fold increase of risk of composite endpoint occurrence (p = 0.0005, OR = 9.47, 95% CI 2.60–34.45). A significant decrease in Gal-3 concentration was observed in the group of patients after AMI without the endpoint occurrence during observation. |
format | Online Article Text |
id | pubmed-7355423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73554232020-07-23 Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study Święcki, Przemysław Sawicki, Robert Knapp, Małgorzata Kamiński, Karol Adam Ptaszyńska-Kopczyńska, Katarzyna Sobkowicz, Bożena Lisowska, Anna J Clin Med Article Galectin-3 (Gal-3) is a new independent risk factor in the development and severity of coronary artery disease (CAD). The aim of the study was to evaluate whether Gal-3 concentration has prognostic value and if it reflects the progression of atherosclerosis in carotid arteries in patients with CAD after acute myocardial infarction (AMI). The analysis included 110 patients who were hospitalized due to AMI, treated with primary coronary intervention (PCI) and further attended a follow-up visit, and 100 healthy volunteers. The Gal-3 concentration and carotid ultrasound were evaluated at baseline and on a follow-up visit. We found that the Gal-3 concentration in the group with hyperlipidemia decreased during the observation (10.7 vs. 7.9 ng/mL, p = 0.00003). Patients rehospitalized during follow up had higher concentration of Gal-3 in the acute phase of myocardial infarction (MI) (10.7 vs. 7.2 ng/mL, p = 0.02; 10.1 vs. 8.0 ng/mL, p = 0.002, respectively). In the group of patients who had none of the following endpoints: subsequent MI, PCI, coronary artery bypass grafting (CABG) or stroke, there was a decrease in Gal-3 concentration at the follow-up visit. Parameters affecting the frequency of a composite endpoint occurrence are: the presence of atheromatous plaque in the carotid artery (p = 0.017), Gal-3 (p = 0.004) and haemoglobin (p = 0.03) concentration. In multivariate analysis, only Gal-3 concentration higher than 9.2 ng/mL at discharge was associated with a nine-fold increase of risk of composite endpoint occurrence (p = 0.0005, OR = 9.47, 95% CI 2.60–34.45). A significant decrease in Gal-3 concentration was observed in the group of patients after AMI without the endpoint occurrence during observation. MDPI 2020-05-29 /pmc/articles/PMC7355423/ /pubmed/32485853 http://dx.doi.org/10.3390/jcm9061640 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Święcki, Przemysław Sawicki, Robert Knapp, Małgorzata Kamiński, Karol Adam Ptaszyńska-Kopczyńska, Katarzyna Sobkowicz, Bożena Lisowska, Anna Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study |
title | Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study |
title_full | Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study |
title_fullStr | Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study |
title_full_unstemmed | Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study |
title_short | Galectin-3 as the Prognostic Factor of Adverse Cardiovascular Events in Long-Term Follow up in Patients after Myocardial Infarction—A Pilot Study |
title_sort | galectin-3 as the prognostic factor of adverse cardiovascular events in long-term follow up in patients after myocardial infarction—a pilot study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355423/ https://www.ncbi.nlm.nih.gov/pubmed/32485853 http://dx.doi.org/10.3390/jcm9061640 |
work_keys_str_mv | AT swieckiprzemysław galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy AT sawickirobert galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy AT knappmałgorzata galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy AT kaminskikaroladam galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy AT ptaszynskakopczynskakatarzyna galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy AT sobkowiczbozena galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy AT lisowskaanna galectin3astheprognosticfactorofadversecardiovasculareventsinlongtermfollowupinpatientsaftermyocardialinfarctionapilotstudy |